No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AMLX Amylyx Pharmaceuticals
- 1.760
- -0.020-1.12%
Close Apr 26 16:00 ET
- 1.840
- +0.080+4.55%
Post 19:56 ET
119.69MMarket Cap2.51P/E (TTM)
1.840High1.700Low5.22MVolume1.790Open1.780Pre Close9.09MTurnover10.20%Turnover Ratio2.51P/E (Static)68.01MShares30.50052wk High0.28P/B90.00MFloat Cap1.70052wk Low--Dividend TTM51.14MShs Float41.930Historical High--Div YieldTTM7.87%Amplitude1.700Historical Low1.742Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Amylyx Pharmaceuticals Inc (AMLX) and Rhythm Pharmaceuticals (RYTM)
Amylyx Pharmaceuticals: A Hold Rating Amidst Promising but Preliminary HELIOS Trial Results
Hold Rating on Amylyx Pharmaceuticals Amid Uncertainties in Drug Efficacy and Market Prospects
Amylyx Pharmaceuticals Is Maintained at Neutral by Baird
Amylyx Pharmaceuticals Is Maintained at Neutral by Baird
Express News | Baird Maintains Neutral on Amylyx Pharma, Lowers Price Target to $3
Express News | HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $8 Price Target
Comments
$Amylyx Pharmaceuticals(AMLX.US$ flat and searching for the new low. How much lower can it be 😂
Update
$Amylyx Pharmaceuticals(AMLX.US$ Amylyx Pharmaceuticals Announces Interim Data From Phase 2 HELIOS Clinical Trial Of AMX0035 In Adults With Wolfram Syndrome
Benzinga· 4 mins ago
Interim analysis, including eight participants assessed at Week 24, demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metabolism, rather than worsening typically expected with disease progression
- All eight participants met prespecified r...
Benzinga· 4 mins ago
Interim analysis, including eight participants assessed at Week 24, demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metabolism, rather than worsening typically expected with disease progression
- All eight participants met prespecified r...
1
$Amylyx Pharmaceuticals(AMLX.US$
NEWS
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced positive interim data from the Phase 2 HELIOS clinical trial of AMX0035 in adults with Wolfram syndrome. The data showed improvements in pancreatic function, glycemic control, and vision, with all parti...
NEWS
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced positive interim data from the Phase 2 HELIOS clinical trial of AMX0035 in adults with Wolfram syndrome. The data showed improvements in pancreatic function, glycemic control, and vision, with all parti...
1
Analysts predict a revenue drop and higher losses per share for Amylyx Pharmaceuticals, indicating slower sales growth than the market, potentially causing market wariness.
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg